HIMS’ GLP-1 Gamble Folds: Can New Hormone Bets Save the Telehealth Darling?

Recent Surge, Hype, and Underlying Fragility

Over the past year, Hims & Hers Health (NYSE: HIMS) rode the GLP-1 wave as one of the more speculative poster children of telehealth + biotech crossover. The thesis was seductive: ride the obesity/weight-loss mania, offer lower-cost compounded versions of semaglutide, convert that into sticky subscriptions and then monetize adjacent verticals (hormones, diagnostics, primary care).

In Q1 2025, the company reported revenue of \$586 million, doubling year-over-year, alongside \$91.1 million in adjusted EBITDA, and 2.37 million subscribers (up ~38%) as weight-loss drove the top line. HIMS had also laid out bold medium-term targets: \$6.5 billion in revenue and \$1.3 billion in adjusted EBITDA by 2030.

Investor momentum was further fueled by HIMS’ announced partnership with Novo Nordisk in April 2025, allowing HIMS to dispense branded Wegovy via its platform at a discounted rate — a move that many interpreted as granting the company a veneer of pharmaceutical legitimacy. The stock popped on the news, reinforcing belief in a hybrid telehealth / drug dispensary model.

But beneath that froth, structural risks were mounting. HIMS’ model was predicated heavily on compounded GLP-1s — a legal and regulatory loophole only operable under certain conditions (notably drug shortages) — and the company’s pivot to “personalized compounding” would soon clash with regulators and pharma incumbents.

produto:The Art of X: Build a Business That Makes You $100/Day

Novo Pullback and Market Reversal

Less than eight weeks after announcing the Wegovy partnership, Novo Nordisk abruptly terminated the agreement in June 2025, publicly accusing HIMS of “illegal mass compounding and deceptive marketing” of knockoff versions of Wegovy. The stock plunged ~30% on the news, erasing much of 2025’s gains.

Novo’s rationale hinged on HIMS allegedly violating the law that prohibits mass compounding absent a “personalization” justification, along with claims of misleading marketing and intellectual property risks. Pharma observers noted the split undermined HIMS’ credibility — beyond the direct revenue loss — by removing a major brand endorsement and exposing the company to potential litigation over its compounding practices.

Compounding had always been HIMS’s lever to reduce cost and margins: in Q2 2025, HIMS reported ~\$190 million in GLP-1–related revenue, down ~\$40 million from the previous quarter, attributing the dip in part to its shift toward “personalized” compounded offerings with lower per-order margins. The loss of the Wegovy channel and regulatory headwinds accelerated the pressure.

Regulatory Fault Lines: FDA, Compounding Rules & FTC Exposure

FDA’s Shortage Rationale, Then Reversal

One core pillar of HIMS’ compounding thesis was the FDA’s historical policy that permits compounding of otherwise patented drugs when the reference drug is in shortage. HIMS leveraged that allowance to supply semaglutide-based products when Wegovy was reportedly in constrained supply. However, in early 2025 the FDA declared that Ozempic / Wegovy shortages had been resolved, triggering a 60–90 day window for compounders to halt production.

That regulatory pivot is existential: once the shortage exemption is removed, many of HIMS’ compounding operations arguably lose legal footing. HIMS publicly acknowledged the risk: it “cannot guarantee it will be able to continue offering these products in the same manner, to the same extent, or at all.”

Limits of the “Personalization Exemption”

HIMS defends its practices by invoking the “personalization exemption” — that compounding done for a specific individual patient per prescription does not count as a mass compounding violation. But regulators and legal scholars argue that HIMS’s scale and marketing suggest the company is operating far beyond narrow personalization. Indeed, Novo cited precisely that boundary cross as grounds for termination.

FTC, Advertising & Deceptive Claims Risk

Another line of regulatory exposure lies not in drug approval but in consumer protection: HIMS has faced criticism and warning letters (or threat thereof) concerning how its marketing frames compounded products as equivalent to FDA-approved versions. Novo itself ran counter-ads (“Check Before You Inject”) pointing out discrepancies in purity, dosing, and oversight.

While compounding pharmacies are regulated under pharmacy rules, marketing claims fall under the FTC’s purview — giving the FTC a possible role in policing claims about efficacy, safety, or comparisons to branded drugs.

Litigation & IP Risk

Novo Nordisk and other GLP-1 drug makers have aggressively litigated against compounding pharmacies and competitors selling unlicensed copies. HIMS may now be in crosshairs for deceptive advertising, IP infringement, or violations of corporate practice-of-medicine laws. Analysts had previously noted that the Novo alliance helped suppress litigation risk; once severed, that overhang returns. The traditional timeline for such suits is 18–24 months, meaning the next 1–2 years could be drawn out legal theater.

Pivoting Into Hormones, Longevity & Diagnostics

With its GLP-1 engine under threat, HIMS is leaning harder into hormonal health (menopause / perimenopause, testosterone) and adjacent diagnostics/consumer lab services.

Menopause / Perimenopause Launch

On October 15, 2025, HIMS’ “Hers” brand unveiled its specialty platform for perimenopause and menopause care, offering treatment plans (e.g. estradiol, progesterone) via pills, patches and creams. The company signaled its ambition for the Hers vertical to surpass $1 billion in revenue in 2026.

This vertical follows a pattern: telehealth firms that once chased GLP-1 are now leaning into hormone replacement therapy (HRT). STAT reports that several companies are making similar pivots. The pitch: recurring demand, medical necessity, and more defensible regulatory boundaries (though still not risk-free) compared to compounding GLP-1.

Testosterone & Low T

Already, HIMS has teased expansion into low testosterone therapies for men, combining home testing, diagnostics, prescription and care. The company also acquired at-home lab testing capabilities to support this push.

Diagnostics, Lab & Longevity

Beyond hormones, HIMS is building diagnostics infrastructure — leveraging home labs, deeper biomarkers, and a data-driven health backbone. CEO Dudum has repeatedly framed the long-term goal as building a “personalized health operating system” spanning multiple specialties.

These non-GLP verticals can, in theory, generate more stable, subscription-based margins with lower regulatory and IP friction — if adoption is real and retention holds.

Scenario Analysis & Key Risks

To gauge whether HIMS can recover its luster, we can map out optimistic, base, and pessimistic paths.

| Scenario | Key Assumptions | Outlook | Risks / Caveats |
| --------------- | ----------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------- |
| Optimistic | Hormone verticals scale swiftly (Hers > \$1B 2026), diagnostics stick, litigation minimal, alternative weight-loss models work | HIMS regains investor trust, trades toward growth comps (~8–12× EV/EBITDA), 5–6x revenue multiple on \$3–4b revenue | Execution risk, competition from incumbents, regulatory shifts in HRT space |
| Base case | Hormone growth moderate, some churn, GLP-1 business declines gradually, moderate legal and regulatory drag | Modest multiple compression, stagnating share, valuation range bound | Capital allocation drain, investor patience runs dry |
| Pessimistic | Litigation enforces divestment of compounding, core GLP-1 collapse, hormone effort fails to scale, regulatory crackdown | Equity impaired, maze of restructuring, possible M&A or pivot exit | Cash burn, reputational damage, collapse of the hype narrative |

Capital & Burn Sensitivity

Even in base and optimistic cases, scaling into new verticals — especially with lab and diagnostic ops — requires meaningful investment. If core GLP-1 revenue decays faster than expected, cash flow may deteriorate before new lines mature. Investor patience is limited in high-volatility telehealth/biotech hybrids.

Competition & Reimbursement Risk

HRT and diagnostics may attract more competition (e.g. established telehealth players, specialist providers). Insurance reimbursement, regulatory coverage, and clinical adoption are nontrivial obstacles.

Regulation & Litigation Overhang

Adverse rulings in compounding lawsuits, stronger FDA/FTC oversight, or new statutory frameworks could further curtail activities. The regulatory pendulum in U.S. drug markets can swing fast.

produto:The Art of X: Build a Business That Makes You $100/Day

Verdict & Positioning

From a fundamental perspective, HIMS’ original high-growth, high-margin story hinged on a regulatory arbitrage that has now eroded. The split with Novo Nordisk exposed how structurally precarious that foundation was. The compounding engine — once the core growth driver — is now in the crosshairs.

Still, HIMS is not necessarily dead in the water. Its pivot toward hormone care, diagnostics, and a broader “platform health” model offers plausible tailwinds — if and only if execution is swift, capital efficient, and retains consumer / clinical credibility. The launch of menopause / perimenopause specialty is a signal that management is leaning hard into this path.

From an equity-risk lens, HIMS remains best suited for investors comfortable with high volatility, binary outcomes, and regulatory betas. It is not for conservative shorts. If the hormone verticals validate, there is upside; if legal or regulatory backlash intensifies, downside could be steep.

My baseline view is cautious: HIMS may achieve a “survivor’s multiple” rather than reclaiming full upside. I would wait for early signs — metrics around hormone-adoption retention, margins, cost control, and any court/litigation developments — before materially re-entering.

---

FAQ

Q: Why did HIMS rely so heavily on compounded GLP-1s?
A: The company exploited regulatory flexibility during drug shortages, offering lower-cost semaglutide analogues via compounding pharmacy networks, which allowed cheaper direct-to-consumer weight-loss prescriptions.

Q: Is compounding illegal under U.S. law now?
A: Not categorically. Compounding remains legal under narrow “personalization” exemptions. The issue is whether HIMS’ scale and marketing cross the line into mass compounding, which is prohibited once the FDA lifts a drug’s shortage status.

Q: Can the hormone verticals realistically replace GLP-1 revenue?
A: Potentially — menopause, perimenopause, HRT, testosterone — are large addressable markets. But that potential depends critically on clinical adoption, retention, pricing power, and capital discipline.

Q: What are the key watch items for HIMS from here?
A: Signs of legal or regulatory enforcement, hormone vertical growth (revenue, margins, churn), capital burn trajectory, and whether compounding litigation surfaces.

---

Sources and Further Reading

• Reuters – “Hims & Hers warns its compounded weight-loss drugs could be constrained” (Feb 2025)
• FierceHealthcare – “Hims & Hers Q1 revenue doubles, boosted by weight-loss demand” (Apr 2025)
• FierceHealthcare – “Hims stock plunges after Novo Nordisk terminates Wegovy deal” (Jun 2025)
• BioSpace – “Novo Nordisk ends Hims & Hers partnership amid compounding controversy” (Jun 2025)
• Pharmacy Times – “Inside the compounded GLP-1 crisis” (Jul 2025)
• STAT News – “Telehealth firms pivot from GLP-1 drugs to hormone therapy” (Mar 2025)
• Hims Investor Relations – “Hers launches menopause and perimenopause specialty” (Oct 2025)

---